Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc has filed its Definitive Proxy Statement for the 2026 Annual General Meeting of Shareholders (AGM), scheduled for July 23, 2026, in Dublin, Ireland. The meeting agenda includes the election of three director nominees, ratification of KPMG as independent auditors, an advisory vote on executive compensation, and proposals to grant the board authority to allot and issue ordinary shares. The record date for shareholders eligible to vote is May 28, 2026.

Jazz Pharmaceuticals plc announced that Anne O Riordan, a Class III director, has informed the board that she will not seek re-election at the company's 2026 annual meeting of shareholders. Her decision was not a result of any dispute or disagreement with the company or its board. The company's board of directors will continue to assess its composition and manage board succession.

Jazz Pharmaceuticals plc reported a strong first quarter for 2026, with total revenues increasing by 19.1% to $1,068.9 million. The company achieved a net income of $293.1 million, a substantial turnaround from a net loss in the prior year period, driven in part by a $122.8 million gain from the sale of a Priority Review Voucher. Basic EPS improved significantly to $4.73.

Jazz Pharmaceuticals plc announced strong first-quarter 2026 financial results, with total revenues reaching $1.1 billion, marking a 19% year-over-year increase. The company reported GAAP diluted EPS of $4.43 and non-GAAP adjusted diluted EPS of $6.34, alongside generating $408 million in cash from operations. Key products like Xywav, Epidiolex, and Zepzelca demonstrated significant sales growth. Additionally, the FDA granted Priority Review for zanidatamab's sBLA in 1L HER2+ GEA, with a PDUFA date set for August 25, 2026, and Jazz Pharmaceuticals reaffirmed its full-year 2026 financial guidance.

Jazz Pharmaceuticals plc filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company confirmed its status as a well-known seasoned issuer and a large accelerated filer, indicating its compliance with SEC reporting requirements. This filing provides updated or corrected information to its previously submitted annual report.